S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway

Insmed (INSM) Competitors

$28.06
+0.34 (+1.23%)
(As of 03/1/2024 ET)

INSM vs. ACAD, RARE, OGN, FOLD, AXSM, MDGL, ARWR, BHVN, RYZB, and ALKS

Should you be buying Insmed stock or one of its competitors? The main competitors of Insmed include ACADIA Pharmaceuticals (ACAD), Ultragenyx Pharmaceutical (RARE), Organon & Co. (OGN), Amicus Therapeutics (FOLD), Axsome Therapeutics (AXSM), Madrigal Pharmaceuticals (MDGL), Arrowhead Pharmaceuticals (ARWR), Biohaven (BHVN), RayzeBio (RYZB), and Alkermes (ALKS). These companies are all part of the "pharmaceutical preparations" industry.

Insmed vs.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Insmed (NASDAQ:INSM) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, community ranking, risk, analyst recommendations and media sentiment.

ACADIA Pharmaceuticals currently has a consensus target price of $36.11, indicating a potential upside of 50.38%. Insmed has a consensus target price of $45.10, indicating a potential upside of 60.73%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than ACADIA Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ACADIA Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.87
Insmed
0 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, ACADIA Pharmaceuticals had 34 more articles in the media than Insmed. MarketBeat recorded 61 mentions for ACADIA Pharmaceuticals and 27 mentions for Insmed. ACADIA Pharmaceuticals' average media sentiment score of 0.44 beat Insmed's score of -0.01 indicating that Insmed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ACADIA Pharmaceuticals
13 Very Positive mention(s)
5 Positive mention(s)
12 Neutral mention(s)
7 Negative mention(s)
1 Very Negative mention(s)
Neutral
Insmed
5 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

ACADIA Pharmaceuticals has higher revenue and earnings than Insmed. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$726.44M5.45-$215.98M-$0.38-63.18
Insmed$305.21M13.65-$749.57M-$5.34-5.25

ACADIA Pharmaceuticals received 368 more outperform votes than Insmed when rated by MarketBeat users. Likewise, 73.02% of users gave ACADIA Pharmaceuticals an outperform vote while only 64.59% of users gave Insmed an outperform vote.

CompanyUnderperformOutperform
ACADIA PharmaceuticalsOutperform Votes
866
73.02%
Underperform Votes
320
26.98%
InsmedOutperform Votes
498
64.59%
Underperform Votes
273
35.41%

ACADIA Pharmaceuticals has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

ACADIA Pharmaceuticals has a net margin of -8.44% compared to ACADIA Pharmaceuticals' net margin of -245.59%. ACADIA Pharmaceuticals' return on equity of 0.00% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals-8.44% -15.67% -9.15%
Insmed -245.59%N/A -53.34%

96.3% of ACADIA Pharmaceuticals shares are owned by institutional investors. 27.5% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats Insmed on 11 of the 18 factors compared between the two stocks.


Get Insmed News Delivered to You Automatically

Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INSM vs. The Competition

MetricInsmedPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$4.17B$6.91B$5.10B$7.63B
Dividend YieldN/A2.84%2.82%3.87%
P/E Ratio-5.258.83183.5515.09
Price / Sales13.65442.623,109.64107.83
Price / CashN/A19.80100.2955.57
Price / Book-12.534.694.534.53
Net Income-$749.57M$159.65M$114.85M$211.55M
7 Day Performance2.86%7.82%5.73%3.36%
1 Month Performance-0.43%15.78%12.81%6.70%
1 Year Performance36.21%8.30%12.92%7.44%

Insmed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACAD
ACADIA Pharmaceuticals
3.9791 of 5 stars
$26.36
+1.8%
$36.26
+37.6%
+18.3%$4.33B$517.23M-28.65580Earnings Report
Analyst Upgrade
Insider Selling
Short Interest ↑
Analyst Revision
News Coverage
RARE
Ultragenyx Pharmaceutical
4.5079 of 5 stars
$53.66
+6.8%
$92.20
+71.8%
+19.2%$4.42B$434.25M-6.441,276Analyst Report
Analyst Revision
OGN
Organon & Co.
4.9728 of 5 stars
$18.04
+2.2%
$23.67
+31.2%
-27.2%$4.61B$6.26B4.5110,000Positive News
FOLD
Amicus Therapeutics
4.1712 of 5 stars
$13.85
+0.5%
$17.20
+24.2%
+4.8%$4.06B$329.23M-23.47484Analyst Report
Short Interest ↑
Analyst Revision
News Coverage
AXSM
Axsome Therapeutics
4.4552 of 5 stars
$84.00
+2.1%
$116.10
+38.2%
+26.2%$3.97B$270.60M-16.15502Analyst Report
MDGL
Madrigal Pharmaceuticals
3.9922 of 5 stars
$239.80
+3.1%
$294.14
+22.7%
-7.8%$4.73BN/A-12.4692Earnings Report
Analyst Report
Analyst Revision
News Coverage
ARWR
Arrowhead Pharmaceuticals
4.4014 of 5 stars
$31.17
+2.2%
$51.25
+64.4%
+11.3%$3.86B$240.74M-11.21525Short Interest ↑
Positive News
BHVN
Biohaven
1.6255 of 5 stars
$47.60
+3.1%
$47.50
-0.2%
+244.0%$3.82B$462.51M-6.64202Analyst Report
News Coverage
RYZB
RayzeBio
0.4697 of 5 stars
$62.49
flat
$31.33
-49.9%
N/A$3.74BN/A0.0088Upcoming Earnings
ALKS
Alkermes
2.7972 of 5 stars
$29.70
-1.1%
$32.50
+9.4%
+11.2%$4.96B$1.66B14.352,100Positive News

Related Companies and Tools

This page (NASDAQ:INSM) was last updated on 3/3/2024 by MarketBeat.com Staff